For the latest quarter, the healthcare company reported earnings of $1 per share on revenue of $3.9 billion.
Analysts had expected the company to report earnings of 95 cents per share on revenue of $3.77 billion.
In the same quarter the previous year, the company reported earnings of $1.26 per share on revenue of $4.26 billion.
"The spin-off of Baxalta was a historic event for the company, and we are excited to embark on this new chapter for Baxter with a newfound focus and vision that furthers our mission to help save and sustain lives,'' CEO Robert L. Parkinson stated.
On July 1, the company's bio-pharmaceutical business, Baxalta (BXLT) , spun-off, and began trading as a public company on the New York Stock Exchange.
On Wednesday, shares of Baxter International closed up 1.08% to $38.50.
Baxter International develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Separately, TheStreet Ratings team rates BAXTER INTERNATIONAL INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
"We rate BAXTER INTERNATIONAL INC (BAX) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share."
You can view the full analysis from the report here: BAX Ratings Report